Navigation Links
Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts

Heightened interest in therapeutic efficiency, quality and safety of food supply, as well as increasing concerns about environmental contamination, drive the biotechnology market. Biopharmaceuticals is poised to experience spiraling growth given the recent success of commercialized products and the steady stream of products presently in the pipeline.

San Jose, California (PRWEB) September 11, 2008 -- Biotechnology industry is regarded as one of the most capital intensive and research-intensive industries. Competitive success and growth in the industry is hugely dependent on the ability to secure needed capital. Majority of companies cannot pivot on product revenues to meet these needs because of the time required to bring new products to market. Instead, the industry has used a wide variety of mechanisms, ranging from venture capital investments and public investments, joint ventures and partnerships with other companies to pump the money required to fuel the industry's growth. Regulation will also continue to remain a key factor influencing the growth of the biotechnology industry, especially for recombinant DNA technology based products. In the upcoming years, the world biotechnology industry is expected to make substantial progress fueled by private funding, collaborative research communities, and commercial opportunities.

Biotechnology has been recognized as a key growth technology by most industrialized countries. While the United States industry leads the global [biotechnology market] in terms of discovery and product sales, Japan, Asia and the Europe are coordinating government, academic and industrial resources in biotechnology development to establish a strong, government-supported technology network.

Biotechnology has a wide range of opportunities, especially in agriculture, human and animal health, molecular biotechnology and the environment sectors. The acceleration of drug discovery and commercialization process resulting from biotechnology is contributing to growing applications in [biopharmaceuticals market]. Biotechnology companies in the pharmaceuticals arena focus on discovering and developing drugs to diagnose, prevent, treat and cure critical diseases. Major biotech drugs available in the market include antibiotics, cancer drugs, anemia drugs, and drugs for multiple sclerosis, arthritis, neutropenia, Alzheimer's disease, infectious diseases, diabetes, AIDS and heart disease. Additionally, over 300 biotech drugs comprising products and vaccines are under clinical trial for a wide range of therapeutic conditions. The market for contract biologics manufacturing is sharply rising with the growth of the biopharmaceuticals sector. Contract biologics manufacturing is rising for specialized technologies and the segment accounts over 20% of total biopharmaceutical manufacturing.

Utilization of biotechnology for the development of agriculture related products and processes would represent a key strategic factor to improve the quality and quantity of production in the country. [Agricultural biotechnology market] is burgeoning, as a result of acceptance of genetic engineering and biotech crops and improved regulatory framework in areas including agricultural research policy, consumer preference, marketing and production, worldwide food demand and industry structure. Biotechnology companies are engaged in myriad activities such as designing of transgenic and genetically modified crops, production of bio-pesticide inoculates, micro-propagation enhancement, food, embryos, pulp, and disease diagnosis.

The report titled "Biotechnology: A Global Outlook" provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. The report offers a bird's eye view of the Biotechnology industry. Annotated with 26 fact, and data rich tables presenting analytical segmentation by product application, the report provides global revenues, and expenditure on R&D of/by biotechnology companies, sales of enabling technologies, biologic drug sales by product and global biotech/pharmacogenomics/bioinformatics product/technology sales, among others. The report also includes an indexed, easy-to-refer, fact-finder directory listing the addresses, and contact details of 2,223 companies worldwide.

For more details about this research report, please visit

About Global Industry Analysts, Inc. [Global Industry Analysts, Inc., (GIA)] is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Web Site


Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related biology technology :

1. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
2. Lumenis Ltd. Announces Appointment of Corporate Vice President, Business Development in support of the companys long-term growth strategy
3. PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
4. DuPont Well Positioned for Long-Term Growth in Agricultural Productivity, Safety and Security, Renewable Energy
5. Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy
6. ALS Therapy Development Institute and California Stem Cell, Inc. Announce Long-Term Scientific Collaboration
7. BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana
8. Ohio Academic Institutions Increase Research and Development Investments
9. The Pittsburgh Life Sciences Greenhouse Tops $10M in Company Investments
10. Lilly CEO Urges Policy Prescriptions to Help Ensure Public and Private Biotech Investments Generate Dividends and U.S. Job Growth
11. MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments
Post Your Comments:
Related Image:
Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts
(Date:11/24/2015)... Mass. (PRWEB) , ... November 24, 2015 , ... ... to maintain healthy metabolism. But unless it is bound to proteins, copper is ... of Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic ...
(Date:11/24/2015)... -- Clintrax Global, Inc., a worldwide provider of clinical research services headquartered ... the company has set a new quarterly earnings record in Q3 ... posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , with ...
(Date:11/24/2015)... ... , ... The Academy of Model Aeronautics (AMA), led by its Executive Council, ... Grand Prix, to represent the First–Person View (FPV) racing community. , FPV racing has ... type of racing and several new model aviation pilots have joined the community because ...
(Date:11/24/2015)... Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on December 29, 2015 at 11:00 a.m. Israel ... Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... of Eric Paneth and Izhak Tamir to the ... Rami Skaliter as external directors; , approval of an amendment to ...
Breaking Biology Technology:
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
(Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
Breaking Biology News(10 mins):